Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From NeuroTronik, Inc.
Deal Watch: Lilly Teams With Regor On Metabolic Disorders
Chinese firm RareStone licenses Rhythm’s Imcivree in greater China and will help enroll label-expansion studies for the drug. Omeros sells ophthalmic surgery drug Omidria and its commercial team to Rayner Surgical Group.
Device/Diagnostics Quarterly Deal-Making Statistics, Q2 2017
Device and diagnostics fundraising slumped in Q2, but there was a substantial uptick in M&A activity. Device financings totaled just slightly over half of the previous quarter, while acquisitions grew almost six-fold, thanks primarily to Becton Dickinson's $23.5 billion play for CR Bard. Financing in diagnostics slid to $1.03 billion, less than half of Q1, whereas the $1.7 billion in M&As (most of that from PerkinElmer's $1.3 billion buy of EuroImmun) was more than double Q1's aggregate.
Series B Pumps $15m Into Abiomed-Backed Acute HF Start-Up
Magenta Medical Ltd, an Israeli start-up founded by cardiology veterans and backed by miniaturized heart pump specialist Abiomed, has reeled in $15m in Series B financing. The additional capital will enable the company to take its catheter-based therapy for acute heart failure through clinical trials and beyond CE-mark approval.
Medtech VCs Show Steady Hand With Dollars Invested in 2013
Despite contraction in the number of funds and VC firms investing in life sciences, 2013 was a strong year for private investing in medtech, with private investors putting $2.54 million into 129 medical device deals, according to Informa’s Strategic Transactions. Looking at where investors placed their money revealed some emerging trends.
- Medical Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Surgical Equipment & Devices
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.